HF
IMUX icon

HRT Financial’s Immunic IMUX Stock Holding History

HRT Financial’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-49,339
Closed -$547K – 4752
2026
Q1 		$547K Buy
+49,339
New +$442K ﹤0.01% 2450
2023
Q3 		– Sell
-1,265
Closed -$31K – 2719
2023
Q2 		$31K Buy
+1,265
New +$21.2K ﹤0.01% 2060
2019
Q1 		– Sell
-35
Closed -$2K – 656
2018
Q4 		$2K Buy
+35
New +$4.1K ﹤0.01% 569

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

HRT Financial's IMUX Position: Q2 2026 in Review

HRT Financial sold out of Immunic (IMUX) in Q2 2026, closing a stake of 49,339 shares — an estimated $547K sold.

HRT Financial first reported a position in IMUX in Q4 2018 and held it in 3 quarters. The position peaked at $547K in Q1 2026. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • HRT Financial reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 49,339 Immunic shares in Q2 2026, an estimated $547K.
  • HRT Financial first reported a position in Immunic in Q4 2018 and held it in 3 quarters.
  • HRT Financial's Immunic position peaked at $547K in Q1 2026.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.